Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 296 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Versus Graft Host Disease Clear all
Terminated Phase 2 Interventional Results available

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

NCT01226420
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Alefacept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 13, 2026, 6:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Glasdegib for Chronic Graft-Versus-Host Disease

NCT04111497
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Fasciitis
Interventions
Glasdegib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclosporine ophthalmic emulsion, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

Study of Nasal Irrigation Versus Nasal Spray for Chronic Nasal and Sinus Symptoms

NCT00318006
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
saline irrigation, saline spray
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 13, 2026, 6:12 PM EDT
Terminated Phase 2 Interventional Results available

Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

NCT03395340
View directory record Official record
Conditions
Graft Versus Host Disease, JNS Kinase, Topical Administration
Interventions
Ruxolitinib 1.5% cream, vehicle cream
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
12 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 13, 2026, 6:12 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Placebo, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Early Phase 1 Interventional

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT02117115
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Multiple Myeloma
Interventions
Dynamic contrast-enhanced computed tomography, Ioversol
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 13, 2026, 6:12 PM EDT
Terminated Phase 1 Interventional Results available

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

NCT02231710
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
Interventions
BPX-501 and Rimiducid
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
4 Months to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 13, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

NCT05236062
View directory record Official record
Conditions
Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Interventions
Exercise, Attention control
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 3 Interventional

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT00031824
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
cyclosporine, hydroxychloroquine, prednisone, tacrolimus
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 29 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
89
States / cities
Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 13, 2026, 6:12 PM EDT
Active, not recruiting No phase listed Observational

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

NCT02611180
View directory record Official record
Conditions
Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
Interventions
Skin punch biopsy, Peripheral blood draw
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation

NCT02250300
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
MLN9708 (2.3 mg), MLN9708 (4.0 mg), MLN9708 (3.0 mg)
Drug
Lead sponsor
Mehdi Hamadani
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 13, 2026, 6:12 PM EDT
Completed No phase listed Observational

Feasibility Study of Collecting Multicenter Chronic GVHD Data

NCT00506233
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

NCT02743351
View directory record Official record
Conditions
Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
Interventions
ProTmune, Control Arm
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 13, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional

A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant

NCT05675930
View directory record Official record
Conditions
Graft-Versus-Host Disease, GVHD, Undefined
Interventions
Photobiomodulation Therapy, Placebo sham device
Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
4 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Bethesda, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 2 Interventional

Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease

NCT00006417
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Stem cell transplantation
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 2 Interventional

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

NCT00346359
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 2 Interventional

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

NCT00003335
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 54 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 13, 2026, 6:12 PM EDT
Terminated Not applicable Interventional

Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)

NCT01964625
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
PET-CT Scan
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

NCT00255710
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 13, 2026, 6:12 PM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Extracorporeal Photopheresis (ECP), Methoxsalen
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 13, 2026, 6:12 PM EDT
Terminated Phase 2 Interventional

A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

NCT04640025
View directory record Official record
Conditions
Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease
Interventions
itacitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
Duarte, California • Aurora, Colorado • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 13, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

NCT03082677
View directory record Official record
Conditions
Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
Interventions
Ixazomib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 13, 2026, 6:12 PM EDT
Completed No phase listed Observational

Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.

NCT01174277
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure, Graft Versus Host Disease
Interventions
Collection of blood sample
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
7 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 13, 2026, 6:12 PM EDT